Success Metrics

Completion Rate

0%(0/1)

Active Trials

4(80%)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph phase_1

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Recruiting3

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

terminated120%

active_not_recruiting120%

recruiting360%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

NCT05030298

active_not_recruitingphase_1

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318

recruitingphase_1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

NCT06650163

terminatedphase_2

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

NCT04469699

recruitingphase_1

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

NCT06418113

Clinical Trials (5)

Showing 5 of 5 trials

NCT05030298Phase 1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Recruiting

NCT03152318Phase 1

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Active Not Recruiting

NCT06650163Phase 1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Recruiting

NCT04469699Phase 2

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Terminated

NCT06418113Phase 1

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 5